2023 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 证券代码：002252 证券简称：上海莱士 公告编号：2024-032 上海莱士血液制品股份有限公司 1、本次股东大会不存在增加、变更、否决提案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议； 3、本次会议涉及股东大会特别决议事项，需经出席会议股东（包括股东代理人） 所持表决权 2/3 以上表决同意后方可通过。 一、会议召开和出席情况 （一）会议召开情况 1、现场会议召开时间为：2024 年 5 月 21 日（星期二）14:00； 网络投票时间为：2024 年 5 月 21 日（星期二）； 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2024 年 5 月 21 日的交易时间，即 9:15－9:25，9:30－11:30，13:00－15:00；通过深圳证券交易所 互联网投票系统投票的具体时间为：2024 年 5 月 21 日 9:15 至 15:00 期间的任意时间。 2、现场会议召开地点：上海市奉贤区南桥新城展园路 398 号南郊宾馆； 3 ...

北京市中伦（上海）律师事务所 关于上海莱士血液制品股份有限公司 2023 年度股东大会的 法律意见书 二〇二四年五月 法律意见书 北京市中伦（上海）律师事务所 关于上海莱士血液制品股份有限公司 2023 年度股东大会的 法律意见书 致：上海莱士血液制品股份有限公司（以下简称"公司"） 北京市中伦（上海）律师事务所（以下简称"本所"）接受公司的委托，指 派律师出席并见证公司2023年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》 （以下简称"《股东大会规则》"）、《律师事务所从事证券法律业务管理办法》 （以下简称"《证券法律业务管理办法》"）、《律师事务所证券法律业务执业 规则（试行）》（以下简称"《证券法律业务执业规则》"）等相关法律、行政 法规、规章、规范性文件及《上海莱士血液制品股份有限公司章程》（以下简称 "《公司章程》"）的规定，就本次会议的召集与召开程序、召集人资格、出席 会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见书。 对本法律意见书的出具，本所律师特 ...

证券代码： 002252 证券简称：上海莱士 上海莱士血液制品股份有限公司投资者关系活动记录表 编号： 2024-004 投资者关系活 □特定对象调研 □ 分析师会议 动类别 □ 媒体采访 √ 业绩说明会 □ 新闻发布会 □ 路演活动 □ 现场参观 □ 其他 （请文字说明其他活动内容） 参与单位名称 投资者网上提问 及人员姓名 时间 2024年5月13日 (周一) 下午 15:00~17:00 地点 公司通过全景网“投资者关系互动平台”（https://ir.p5w.net）采用网络远程 的方式召开业绩说明会 上市公司接待 1、董事长、总经理Jun Xu（徐俊） 人员姓名 2、独立董事彭玲 3、副总经理、董事会秘书刘峥 4、财务负责人陈乐奇 1、海尔即将成为公司控股股东，海尔对于公司未来发展战略会不会 进行调整，在公司获取浆站资源、产品创新方面是如何规划？另外，现 在已有合成生物重组蛋白产品问世，我认为该新产品对公司而言是机遇 也是挑战，公司如何应对合成生物技术对血制品行业所带来的风险，采 取哪些措施来规避风险？ 回复：您好！感谢您对我公司的关心和支持！ ...

Investment Rating - The report maintains a "Buy" rating for the company [3]. Core Views - The company's annual revenue met expectations, but investment losses impacted profits. The self-produced blood products business showed steady growth, and the agency business contributed additional revenue. The forecasted EPS for 2024 has been raised to 0.37 yuan from 0.35 yuan, with a target price of 10.09 yuan based on a PE of 27X for 2024 [1][2]. Financial Summary - The company reported a revenue of 7,964 million yuan in 2023, a year-on-year increase of 21.3%. The net profit attributable to shareholders was 1,779 million yuan, down 5.4% from the previous year. The net profit excluding non-recurring items was 1,815 million yuan, a slight decrease of 0.6% [2][8]. - The gross profit margin decreased by 3.37 percentage points to 40.79%, primarily due to a decline in the gross margin of imported albumin products [1][2]. - For Q1 2024, the company reported a revenue of 2,056 million yuan, a slight decrease of 0.3%, while the net profit attributable to shareholders increased by 5.3% to 757 million yuan [1][2]. Business Performance - The self-produced blood products business developed steadily, with a record plasma collection volume exceeding 1,500 tons in 2023. Revenue from self-produced blood products reached 4,317 million yuan, up 14.5% year-on-year. Notably, the revenue from immunoglobulin increased significantly by 37.5% to 1,805 million yuan [1][2]. - The agency business for imported albumin and testing services continued to contribute additional revenue, with respective revenues of 3,504 million yuan and 141 million yuan, reflecting year-on-year growth rates of 28% and 131% [1][2]. Financial Forecasts - The company forecasts revenues of 8,593 million yuan for 2024, 9,520 million yuan for 2025, and 10,368 million yuan for 2026, with respective growth rates of 8%, 11%, and 9% [2][8]. - The forecasted EPS for 2025 is 0.40 yuan and for 2026 is 0.43 yuan [1][2]. Market Data - The current stock price is 7.45 yuan, with a target price of 10.09 yuan, indicating a potential upside [3][4]. - The company has a market capitalization of 49,509 million yuan, with a 52-week price range of 6.20 to 8.47 yuan [4][8]. Valuation Metrics - The report provides a PE ratio of 27.45 for 2023, projected to decrease to 20.10 in 2024 and further to 18.56 in 2025 [2][8]. - The company’s net asset return rate is projected to be 6.0% for 2023, increasing to 7.6% in 2024 [2][8].

证券研究报告：医药生物 | 公司点评报告 2024年5月6日 股票投资评级 上海莱士(002252) 买入|维持 采浆量稳步增长，期待新浆站验收落地 个股表现 ⚫ 事件： 4 月 29 日和 30 日，上海莱士发布 2023 年年报和 2024 年一季 上海莱士 医药生物 26% 报。公司2023全年实现79.64亿元（+21.27%）、归母净利润17.79亿 20% 元（-5.35%）、扣非净利润18.15亿元（-0.58%）。2024年一季度，公 14% 8% 司实现营收20.56亿元（-0.33%）、归母净利润7.57亿元（+5.32%）、 2% 扣非净利润5.90亿元（-16.64%）。 -4% -10% ⚫ 2023年自产血制品稳健增长，代理白蛋白收入占比提升： -16% 2023Q4公司实现营收20.29亿元（+25.56%）、归母净利润-0.08 -22% -28% 亿元（-102.94%）。公司23Q4和全年利润增速下滑主要受GDS长期股 2023-05 2023-07 2023-09 2023-12 2024-02 2024-04 权投资权益法确认的投资损失影响，剔除该影响，公司血制品业务利 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's revenue for 2023 reached 7.96 billion yuan, a year-on-year increase of 21.3%, while the net profit attributable to shareholders was 1.78 billion yuan, a decrease of 5.4% [2] - The company has received approval for clinical trials of its innovative drug SR604, which is aimed at treating hemophilia and congenital factor VII deficiency [2] - Revenue forecasts for 2024-2026 are projected at 9.11 billion yuan, 10.3 billion yuan, and 11.7 billion yuan respectively, with net profits expected to be 2.36 billion yuan, 2.7 billion yuan, and 3.03 billion yuan [2] Summary by Sections Financial Performance - In 2023, the company achieved a total revenue of 79.6 billion yuan, with quarterly revenues of 20.6 billion, 18.4 billion, 20.3 billion, and 20.3 billion yuan, reflecting growth rates of +22.4%, +14.3%, +22.7%, and +25.6% respectively [2] - The self-operated blood products revenue was 4.3 billion yuan, up 15%, while the agency sales of imported human albumin reached 3.5 billion yuan, up 28% [2][10] - The company reported a net profit of 1.78 billion yuan for 2023, with a quarterly breakdown of 720 million, 520 million, 550 million, and a loss of 80 million yuan in Q4 [2] Product Development - The innovative drug SR604 received approval for clinical trials, which is expected to significantly improve patient compliance with a proposed administration schedule of once every four weeks [2] Future Projections - Revenue and net profit forecasts for 2024-2026 indicate a steady growth trajectory, with expected revenues of 91.1 billion yuan in 2024, 103 billion yuan in 2025, and 117 billion yuan in 2026 [2][10] - The company anticipates a strong performance in its self-operated blood products business and an enhanced market position through agency sales of imported human albumin [2]

[Table_StockInfo] 买入 2024年 05月 05日 （维持） 证券研究报告•2023年年报点评 当前价： 7.18元 上海莱士（002252） 医药生物 目标价： ——元（6个月） 全年收入增长符合预期 投资要点 西南证券研究发展中心 [T ab事le件_S：u公m司ma发ry布] 2023年报&2024年一季报，2023年实现收入79.6亿元，同比 [分Ta析bl师e_：Au杜th向or阳] +21.3%，实现归母净利润17.8亿元，同比-5.4%，扣非归母净利润18.2亿元， 执业证号：S1250520030002 同比-0.6%。2024年一季度实现收入 20.6亿元，同比-0.3%，实现归母净利润 电话：021-68416017 7.6亿元，同比+5.4%，扣非归母净利润5.9亿元，同比-16.6%。 邮箱：duxy@swsc.com.cn  23Q4/24Q1 表观利润受投资收益影响。2023 公司各季度收入分别为 分析师：王彦迪 20.6/18.4/20.3/20.3 亿元(+22.4%/+14.3%/+22.7%/+25.6%)，整体收入增长符 执业证号：S12505240 ...

上海莱士血液制品股份有限公司 上海莱士血液制品股份有限公司（以下简称"公司"或"上海莱士"）股东 Grifols, S.A.（以下简称"基立福"或"卖方"）与海尔集团公司（以下简称"海尔集团"）于 2023 年 12 月 29 日签署了《战略合作及股份购买协议》（以下简称"原协议"），海尔 集团或其指定关联方拟协议收购基立福持有的公司 1,329,096,152 股股份，占公司总 股本的 20.00%，转让价款 125.00 亿元；同时，基立福将其持有的剩余公司 437,069,656 股股份对应的表决权委托予海尔集团或其指定关联方行使，占公司总股本的 6.58% （以下简称"本次交易"或"本次权益变动"）。具体内容详见公司于 2023 年 12 月 30 日披露的《关于股东权益变动暨公司控制权拟发生变更的提示性公告》（2023-082 号）公告。 2024 年 1 月 21 日，经基立福与海尔集团协商一致，海尔集团指定全资孙公司 海盈康（青岛）医疗科技有限公司（以下简称"海盈康"或"买方"）作为上述协议 项下的承继方，海尔集团、海盈康与基立福重新签订了《经修订及重述的战略合作 及股份购买协议》（以下简称"新 ...

Investment Rating - The report maintains a "Recommend" rating for Shanghai RAAS (002252) [1] Core Views - In 2023, the company achieved operating revenue of 7.964 billion yuan, a year-on-year increase of 21.27%, with strong performance in its main business [1] - Net profit attributable to shareholders was 1.779 billion yuan, a year-on-year decrease of 5.35%, mainly due to investment losses from GDS equity method accounting [1] - In Q1 2024, operating revenue was 2.056 billion yuan, a slight decrease of 0.33% year-on-year, while net profit attributable to shareholders increased by 5.32% to 757 million yuan [1] - The company's plasma collection volume exceeded 1,500 tons in 2023, reaching a historical high [1] - The company added 3 new plasma collection stations in 2023 through approvals and acquisitions, bringing the total to 44 stations across 11 provinces [1] - The company is developing SR604 injection, a novel monoclonal antibody for hemophilia treatment, which has entered clinical trials and has no competing products globally [1] Financial Performance Revenue and Profit - 2023 revenue: 7.964 billion yuan (+21.27% YoY) [1] - 2023 net profit: 1.779 billion yuan (-5.35% YoY) [1] - 2024 Q1 revenue: 2.056 billion yuan (-0.33% YoY) [1] - 2024 Q1 net profit: 757 million yuan (+5.32% YoY) [1] Product Performance - Human albumin revenue: 4.935 billion yuan (+16.84% YoY), with gross margin of 26.00% [1] - Imported albumin: 3.504 billion yuan (+28.16% YoY), gross margin 18.63% [1] - Self-produced albumin: 1.431 billion yuan (-3.94% YoY), gross margin 44.06% [1] - Intravenous immunoglobulin revenue: 1.805 billion yuan (+37.47% YoY), gross margin 56.63% [1] Financial Projections - 2024-2026 net profit forecast: 2.198/2.530/2.917 billion yuan [1] - 2024-2026 PE ratio: 22/19/16 times [1] - 2024-2026 EPS forecast: 0.33/0.38/0.44 yuan [2] Business Development - The company continues to expand its plasma collection network and optimize existing stations [1] - It is pursuing a dual strategy of internal growth and external expansion through mergers and acquisitions [1] - The company is focusing on enhancing core competitiveness and sustainable development capabilities [1] Research and Development - SR604 injection, a novel hemophilia treatment, has entered clinical trials with a unique mechanism of action [1] - The drug aims to provide subcutaneous injection every 4 weeks, compared to current treatments requiring 2-3 intravenous injections per week [1] - Preclinical research results have been published in the international journal Blood [1] Market Position - The company maintains a leading position in plasma collection volume and station numbers in China [1] - Its plasma stations are distributed across 11 provinces, covering major regions in China [1]

Financial Performance - The company's revenue for Q1 2024 was approximately ¥2.06 billion, a decrease of 0.33% compared to the same period last year[4]. - Net profit attributable to shareholders increased by 5.32% year-on-year, reaching approximately ¥756.82 million[4]. - The net profit after deducting non-recurring gains and losses decreased by 16.64% to approximately ¥590.50 million[4]. - Total operating revenue for the current period is ¥2,056,305,681.88, a slight decrease of 0.35% from ¥2,063,038,679.08 in the previous period[20]. - Net profit for the current period is ¥757,077,509.35, representing an increase of 5.39% compared to ¥718,266,042.76 in the previous period[22]. - Earnings per share (EPS) for the current period is ¥0.114, up from ¥0.107 in the previous period[22]. Cash Flow - The net cash flow from operating activities was approximately ¥750.87 million, down 29.86% from the previous year[4]. - The company reported a decrease in cash flow from operating activities due to reduced receipts and increased payments[9]. - Operating cash flow net amount was $750.87 million, a decrease of 30% compared to $1.07 billion in the previous period[24]. - Cash inflow from operating activities totaled $2.29 billion, slightly down from $2.36 billion year-over-year[24]. - Cash outflow from operating activities increased to $1.54 billion, compared to $1.29 billion in the previous period[24]. - The ending balance of cash and cash equivalents was $4.11 billion, up from $3.63 billion year-over-year[25]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥32.78 billion, an increase of 2.66% from the end of the previous year[4]. - Total assets increased to ¥32,776,666,095.10, compared to ¥31,928,453,993.18 in the previous period, reflecting a growth of 2.66%[19]. - Total liabilities rose to ¥2,316,204,427.85, an increase of 1.00% from ¥2,278,642,620.25 in the previous period[19]. - The total current assets increased to CNY 9.26 billion from CNY 8.68 billion, representing a growth of approximately 6.7%[16]. Investment and Income - Investment income surged by 129.31% to approximately ¥268.70 million, primarily due to gains from the disposal of financial assets[9]. - The company reported investment income of ¥268,696,550.07, significantly higher than ¥117,176,815.83 in the previous period[20]. - The company received $55.70 million in investment income, significantly higher than $23.36 million in the previous period[24]. - Other income increased significantly by 1345.89% to approximately ¥35.10 million, mainly from government subsidies[9]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 96,910[11]. - Grifols, S.A. holds 26.58% of shares, amounting to 1,766,165,808 shares, making it the largest shareholder[11]. - The company reported a total of 1,766,165,808 unrestricted shares held by Grifols, S.A.[12]. - The total number of shares pledged by RAAS China Limited is 235,908,280[11]. Other Financial Metrics - The weighted average return on equity increased by 0.05 percentage points to 2.52%[4]. - Research and development expenses increased to ¥50,086,978.94, up from ¥46,017,682.81 in the previous period, reflecting a growth of 15.00%[20]. - Other comprehensive income after tax for the current period is ¥47,946,690.97, compared to a loss of ¥190,194,831.87 in the previous period[22]. - Unallocated profits increased to ¥9,075,737,765.69, up from ¥8,318,921,646.19 in the previous period, indicating a growth of 9.12%[19].